On June 5, Kohlbotai (6990.HK) announced the issuance of new shares, and implemented the allotment of 5.918 million H shares under the general authorization, accounting for approximately 2.54% of the company's total share capital after issuance, with an allotment price of HK$331.8 and a net raised amount of approximately US$250 million.
It is reported that the additional issuance was subscribed by investors such as international long-term, sovereign funds and medical special funds, and its order scale exceeded the scale of this financing; due to strong bookkeeping demand, the transaction scale increased from the initial US$200 million to US$250 million, becoming the largest new stock issuance transaction in the biopharmaceutical industry in the Hong Kong stock market in the past 12 months; the allocation price was 7.58% discounted from yesterday's closing price, and a premium of 0.89% from the average closing price of the previous five days.
The announcement shows that the financing amount plan is mainly used for product research and development, clinical trials, registration, manufacturing and commercialization, and will further enhance the company's internal R&D technical capabilities, strengthen external cooperation and expand the product pipeline combination.
